Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TERN-201 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| TERN-201 | DRUG | Investigational drug |
| Placebo | OTHER | Matching placebo |
TERN-201 is an investigational small molecule being developed for nonalcoholic steatohepatitis, or NASH, a metabolic liver disease. It has been studied in patients with non-cirrhotic NASH. TERN-201 has not been approved for any indication and remains in clinical development.
TERN-201 targets VAP-1, also known as vascular adhesion protein-1, a protein target. VAP-1 is a semicarbazide-sensitive amine oxidase that contributes to inflammation and immune cell recruitment. By binding VAP-1, TERN-201 is designed to act on inflammatory pathways relevant to NASH.
TERN-201 is being developed by Terns Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker TERN. The company is a clinical-stage biopharmaceutical company focused on metabolic and liver diseases.
TERN-201 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. Its only reported clinical trial to date is a completed Phase 1 study, and no trials are currently listed as active.
TERN-201 has been evaluated in the AVIATION study, registered as NCT04897594. That Phase 1 trial was titled a Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis. It enrolled 52 patients and is now completed.
The Phase 1 AVIATION study, NCT04897594, was an uncontrolled trial with 52 enrolled patients with non-cirrhotic NASH. It was not randomized and not double blinded. The study assessed safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of TERN-201 and is listed as completed.